http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#Head
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#provenance
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#pubinfo
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion
http://purl.obolibrary.org/obo/DOID_2355
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_2355
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00727
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
http://www.w3.org/2000/01/rdf-schema#label
"* Use of phosphodiesterase type 5 (PDE-5) inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil, or soluble guanylate cyclase (sGC) stimulators. (4.1, 7.1) * Severe anemia (4.2) * Increased intracranial pressure (4.3) * Hypersensitivity to nitroglycerin sublingual tablets or to other nitrates or nitrites or any excipient (4.4) * Circulatory failure and shock (4.5) Do not use nitroglycerin sublingual tablets in patients who are taking PDE-5 Inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see Drug Interactions ( 7.1 Do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. Concomitant use can cause hypotension. Nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). Nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). Nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. Nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock."
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00727
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#provenance
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#pubinfo
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig
http://purl.org/nanopub/x/hasSignature
BCGlV4oQp3JkI8KCv6WD6UYS32uTU2nPWr5I6Y9l/KJs28zucIP5dhEAEnYVgDAFHjF7YUzuZqLIRzhUDxNyfBFW2Yy27tDM49Vl3rT4me5yNu9/JZlqnCP9pzz5aV9roQXPzO47SaXxsE61RBiH03ylYPaoBlJCy+7efARtJwQ=
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://purl.org/dc/terms/created
2021-08-23T18:45:39.569+02:00
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAp7xYEwtv0W97jbB3X9lOCTW-NLxXMv6XNtWa96nyxDw
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY